Person: KARAHASAN, AYŞEGÜL
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KARAHASAN
First Name
AYŞEGÜL
Name
7 results
Search Results
Now showing 1 - 7 of 7
Publication Metadata only Predictors of eradication failure at first isolation of MRSA in cystic fibrosis patients(EUROPEAN RESPIRATORY SOC JOURNALS LTD, 2020) KARAHASAN, AYŞEGÜL; Mursaloglu, Huseyin Hakan; Akin, Can; Yilmaz, Cansu; Ergenekon, Pinar; Gokdemir, Yasemin; Eralp, Ela Erdem; Karakoc, Fazilet; Karahasan, Aysegul; Karadag, BulentPublication Metadata only Comparison of intravenous and non-intravenous antibiotic regimens in eradication of P. aeruginosa and MRSA in cystic fibrosis(WILEY, 2021-12) KARAHASAN, AYŞEGÜL; Mursaloglu, H. Hakan; Akin, Can; Yegit, Cansu Yilmaz; Ergenekon, Almala P.; Uzunoglu, Burcu Suzer; Tastan, Gamze; Gokdemir, Yasemin; Eralp, Ela Erdem; Yagci, Aysegul Karahasan; Karakoc, Fazilet; Karadag, BulentBackground Chronic pulmonary infection is the leading cause of mortality and morbidity in patients with cystic fibrosis (CF). The most common pathogens isolated in CF are Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA). Chronic infection of PA and methicillin-resistant S. aureus (MRSA) are associated with worse survival and antibiotic eradication treatment is recommended for both. This study compared the outcomes between intravenous (IV) and non-IV antibiotics in eradication of PA and MRSA. Methods This was a single-center retrospective study. All respiratory specimen cultures of 309 CF patients and eradication regimens between 2015 and 2019 were reviewed. Patients received eradication treatment in case of first ever isolation or new isolation after being infection-free >= 1 year. The primary analysis was the comparison of the percentage of successful eradication after receiving IV and non-IV eradication regimens. Demographic and clinical risk factors for eradication failure were also analyzed. Results One hundred and two patients with PA isolations and 48 patients with MRSA were analyzed. At 1 year, 21.6% in PA group and 35.4% in MRSA group were successfully eradicated. There was not any statistically significant difference between IV versus non-IV antibiotic regimens on eradication in either group. Additionally, none of the clinical risk factors was significantly associated with eradication failure in PA and MRSA groups. Conclusion In the eradication of PA and MRSA, IV and non-IV treatment regimens did not show any superiority to one another. Non-parenteral eradication could be a better option considering the cost-effectiveness and the treatment burden of IV treatments due to hospitalization and the need for IV access.Publication Open Access COVID-19 disease characteristics in different pediatric age groups(2022-01-01) ŞENYÜREK, BETÜL; BORAN, PERRAN; KEPENEKLİ KADAYİFCİ, EDA; YAKUT, NURHAYAT; KARAHASAN, AYŞEGÜL; AYDINER, ELİF; MEMİŞOĞLU, ASLI; GÖKDEMİR, YASEMİN; ERDEM ERALP, ELA; KARADAĞ, BÜLENT TANER; KEPENEKLİ KADAYİFCİ E., YAKUT N., Ergenc Z., Aydiner O., Sarinoglu R. C., KARAHASAN A., Karakoc-Aydiner E., MEMİŞOĞLU A., GÖKDEMİR Y., ERDEM ERALP E., et al.Introduction: Little is known about the COVID-19 disease characteristics and differences between different pediatric age groups. This study aimed to investigate the disease characteristics according to age groups. Methodology: We conducted a retrospective, single-center study of pediatric COVID-19 in a tertiary care hospital in Turkey. The patients were divided into three groups: 15 days-24 months old (Group 1), 25-144 months old (Group 2), and 145-210 months old (Group 3) according to age. Results: A total of 139 pediatric patients with COVID-19 were examined. Twenty-nine patients (20.9%) were in Group 1, 52 (37.4%) were in Group 2, 58 (41.7%) were in Group 3. Thirty-nine patients (28.1%) were hospitalized. The most common symptoms were cough (55.4%) and fever (51.8%). The median chest X-ray (CXR) score of hospitalized patients was 1 (min 0-max 7), and the median CXR score of outpatients was 1 (min 0-max 6). Fever was significantly more frequent in Group 1, and chest pain was more frequent in Group 3. Group 1 had significantly higher WBC, lymphocyte, thrombocyte counts, AST, LDH, D-dimer, and Troponin T levels but lower hemoglobin, total protein, and albumin levels. The treatment included antibiotics, oseltamivir, hydroxychloroquine, and supportive therapy. Only one patient (0.7%) received noninvasive mechanical ventilatory support. Conclusions: As we know the clinical course of COVID-19 in children is less severe than in adults. We also found significant differences in both clinical and laboratory findings between different pediatric age groups which supports the theory that disease pathogenesis is highly variable according to age.Publication Metadata only Cumulative Antimicrobial Susceptibility Data of Pseudomonas Aeruginosa Isolates from Cystic Fibrosis Patients: 4-Year Experience(GEORG THIEME VERLAG KG, 2021) KARAHASAN, AYŞEGÜL; Fidan, Ebru; Alci, Gamze; Koldas, Seda Sevilay; Gokdemir, Yasemin; Karadag, Bulent; Eralp, Ela Erdem; Yagci, Aysegul KarahasanObjective Pseudomonas aeruginosa is the most important cause of lung infection among cystic fibrosis (CF) patients, and to reduce the severity of the infection, facility-specific cumulative antibiograms could help clinicians in empirical treatment. Methods Respiratory samples of CF patients between January 2015 and December 2018 were scanned through Laboratory Operating System retrospectively. Demographical data of patients, culture results, and antibiotic susceptibilities are recorded using Microsoft Excel 2010. Cumulative antibiogram data were obtained according to the CLSI M39A4 document. Results The number of registered patients has increased in 4 years from 154 to 253. The mean age of patients varied from 9 to 11.7 (range, 2-42). The ratio of patients with a positive culture for P. aeruginosa increased from 32 to 40%, and the mean patients' age decreased from 16.6 to 11.1 (p < 0.05). A total number of 4,146 respiratory samples were analyzed. Sputum samples consisted of 42.5% (n: 1,767) of the samples with a 58.4% isolation rate of P. aeruginosa (n: 1,034). A notable increase of resistance was seen almost all antimicrobials tested by years. The ratio of multidrug-resistant (MDR) P. aeruginosa was 4.1, 10.2, 4.5, and 8.6% in 2015, 2016, 2017, and 2018. Conclusion Antimicrobial resistance is a challenging problem in CF patients, and surveillance should be done regularly.Publication Metadata only The Effects of Nebulizer Cleaning and Disinfection Training On The Knowledge Levels and Practises of the Caregivers of Patients with Cystic Fibrosis(EUROPEAN RESPIRATORY SOC JOURNALS LTD, 2020) KARAHASAN, AYŞEGÜL; Yegit, Cansu Yilmaz; Ergenekon, Pinar; Mursaloglu, Hakan; Tastan, Gamze; Uzunoglu, Burcu Suzer; Gokdemir, Yasemin; Eralp, Ela Erdem; Duman, Nurcan; Karahasan, Aysegul; Karakoc, Fazilet; Karadag, BulentPublication Metadata only A review of treatment regimens at first isolation of PA in a single cystic fibrosis center(EUROPEAN RESPIRATORY SOC JOURNALS LTD, 2020) KARAHASAN, AYŞEGÜL; Mursaloglu, Huseyin Hakan; Akin, Can; Yilmaz, Cansu; Ergenekon, Pinar; Gokdemir, Yasemin; Eralp, Ela Erdem; Karakoc, Fazilet; Karahasan, Aysegul; Karadag, BulentPublication Open Access Ki̇sti̇k fi̇brozi̇s ve ki̇sti̇k fi̇brozi̇s dişI hastalardan İzole edi̇len achromobacter türleri̇ İle İlgi̇li̇ retrospekti̇f anali̇z(2022-12-01) KARAHASAN, AYŞEGÜL; KARADAĞ, BÜLENT TANER; ERDEM ERALP, ELA; GÖKDEMİR, YASEMİN; Karahasan A., Gökdemir Y., Karadağ B. T., Erdem Eralp E.Achromobacter türleri Gram negatif, katalaz, oksidaz ve sitrat pozitif, fermentatif olmayan bakterilerdir. Toplum kökenli ya da hastane kaynaklı enfeksiyonlara sebep olabilmektedir. Hem immünokompetan hem de immün yetmezlikli kişilerde enfeksiyonlara sebep olabilmekle birlikte kistik fibrozis (KF) hastalarını enfekte etmeleri durumunda, KF hastalarının akciğer fonksiyonlarını kötüleştirdiğinden ve daha sık pulmoner alevlenmeye neden olduğundan bu hasta grubunda özellikle önem taşımaktadır. Bu retrospektif çalışmada, Marmara Üniversitesi Eğitim ve Araştırma Hastanesi’nde 2017-2021 yıllarında Achromobacter türleri izole edilen hastaların verileri analiz edilmiştir. Altta yatan hastalıkların varlığına göre Achromobacter türlerinin izolasyon sıklığı, hastalara ait demografik veriler ve antimikrobiyal duyarlılık sonuçları irdelenmiştir. İzolatların tür düzeyinde tanımlaması, matriks ile desteklenmiş lazer desorpsiyon/iyonizasyon uçuş zamanı kütle spektrometresi (MALDITOF MS, VITEK MS, BioMérieux, Fransa) ile yapılmıştır. Antimikrobiyal duyarlılık testleri, disk difüzyon metodu ile çalışılmıştır. İstatistiksel analizler için SPSS (Statistical Package for Social Sciences) for Windows 24.0 programı kullanılmıştır. Toplam 148 hastadan 318 Achromobacter izolatı elde edilmiştir. Hastaların %29.7’si kistik fibrozis (KF); %70.3’ü ise KF dışı hastalar olmasına rağmen izolatların %51.6’sı KF hastalarına aittir (P=0.63). En sık gönderilen örnek türü, solunum yollarına ait örnekler olup (%78), KF hastalarında gönderilen örneklerin tümü solunum örneği iken; KF dışı hastalarda bu oran %54.5’tir (P<0.05). Solunum yolu örneklerini %10 oranında idrar, %5.7 kan ve %6.3 diğer örnekler takip etmiştir. Hastaların 47’sinde (%31’inde) tekrarlayan Achromobacter üremesi saptanmıştır. Hasta başına tekrarlayan örnek sayısı 4.6 (2-28) olup KF hasta grubunda 22 hastada (%50), KF dışı hasta grubunda 25 hastada (%32.5) tekrarlayan izolasyon olmuştur. Tüm izolatlarda, KF izolatlarında ve diğer izolatlarda direnç oranları sırasıyla piperasilin/tazobaktam için %25.6, %30.4 ve %21.9; meropenem için %40.0, %61.1 ve %18.0 (P<0.05);trimetoprim/sülfametaksazol için %44.7, %68.2 ve %12.5 (p<0.05) olarak belirlenmiştir. Achromobacter hakkındaki çalışmalar oldukça kısıtlı olmakla birlikte, son yıllarda görülme sıklığı artmaktadır; bu bakteri hakkında daha fazla bilgiye ve araştırmaya ihtiyaç vardır. Çalışmamız verileri, literatüre katkıda bulunarak Achromobacter türlerinde artan antimikrobiyal direncin önemine dikkat çekmektedir.